{"id":"erythropoietin-alfa","safety":{"commonSideEffects":[{"rate":"20-30","effect":"Hypertension"},{"rate":"5-10","effect":"Thrombotic events (deep vein thrombosis, pulmonary embolism)"},{"rate":"10-15","effect":"Headache"},{"rate":"5-10","effect":"Fever"},{"rate":"5-10","effect":"Injection site reactions"}]},"_chembl":{"chemblId":"CHEMBL1201464","moleculeType":"Protein"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Erythropoietin alfa mimics the natural hormone erythropoietin, which regulates red blood cell production in response to tissue hypoxia. By binding to EPO receptors on erythroid progenitor and precursor cells in the bone marrow, it promotes their proliferation, differentiation, and maturation into mature red blood cells. This increases hemoglobin levels and oxygen-carrying capacity of the blood.","oneSentence":"Erythropoietin alfa is a recombinant human erythropoietin that stimulates red blood cell production by binding to erythropoietin receptors on bone marrow progenitor cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:11:28.886Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Anemia associated with chronic kidney disease"},{"name":"Anemia in patients with cancer receiving chemotherapy"},{"name":"Anemia in patients with HIV infection"}]},"trialDetails":[{"nctId":"NCT07463820","phase":"PHASE2","title":"A Trial Comparing Three Different Treatment Options for Adults With Low-Risk Myelodysplasia and Anemia (A MyeloMATCH Treatment Trial)","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-06-19","conditions":"Myelodysplastic Syndrome","enrollment":270},{"nctId":"NCT05564390","phase":"PHASE2","title":"MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-06-18","conditions":"Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm, Acute Myeloid Leukemia Post Cytotoxic Therapy","enrollment":2000},{"nctId":"NCT00843882","phase":"PHASE3","title":"Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2009-01-29","conditions":"Anemia, Chronic Myelomonocytic Leukemia, De Novo Myelodysplastic Syndrome","enrollment":247},{"nctId":"NCT05949684","phase":"PHASE3","title":"ELEMENT-MDS: A Study to Compare the Efficacy and Safety of Luspatercept in Participants With Myelodysplastic Syndrome (MDS) and Anemia Not Receiving Blood Transfusions","status":"RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2023-10-24","conditions":"Myelodysplastic Syndromes","enrollment":360},{"nctId":"NCT06520826","phase":"PHASE3","title":"Vafseo Outcomes In-Center Experience","status":"ACTIVE_NOT_RECRUITING","sponsor":"USRC Kidney Research","startDate":"2024-11-20","conditions":"Anemia of Chronic Kidney Disease","enrollment":2200},{"nctId":"NCT07422480","phase":"PHASE3","title":"A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions","status":"RECRUITING","sponsor":"Takeda","startDate":"2026-04-01","conditions":"Myelodysplastic Syndrome, Anemia","enrollment":300},{"nctId":"NCT06184867","phase":"NA","title":"Choices About Genetic Testing And Learning Your Risk With Smart Technology","status":"COMPLETED","sponsor":"Rutgers, The State University of New Jersey","startDate":"2023-09-26","conditions":"Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer","enrollment":50},{"nctId":"NCT05181735","phase":"PHASE1, PHASE2","title":"Study Evaluating Combination of Luspatercept in LR-MDS Without RS Having Failed or Being Ineligible to ESA","status":"RECRUITING","sponsor":"Groupe Francophone des Myelodysplasies","startDate":"2022-05-18","conditions":"MDS, Myelodysplastic Syndromes","enrollment":150},{"nctId":"NCT05340465","phase":"PHASE2","title":"Darbe Plus IV Iron to Decrease Transfusions While Maintaining Iron Sufficiency in Preterm Infants","status":"RECRUITING","sponsor":"University of Washington","startDate":"2022-11-27","conditions":"Prematurity, Iron-deficiency, Iron Deficiency Anemia","enrollment":120},{"nctId":"NCT06832189","phase":"PHASE1","title":"EVR and EPO for Liver Transplant Tolerance","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2026-01-21","conditions":"Liver Transplant","enrollment":20},{"nctId":"NCT03329196","phase":"PHASE3","title":"Efficacy and Safety Study to Evaluate MT-6548 in Non-dialysis Subjects With Anemia Associated With Chronic Kidney Disease in Japan","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2017-10-30","conditions":"Anemia; Non-dialysis Dependent Chronic Kidney Disease","enrollment":304},{"nctId":"NCT03439137","phase":"PHASE3","title":"Efficacy and Safety Study to Evaluate MT-6548 in Hemodialysis Subjects Currently Receiving ESAs With Anemia Associated With Chronic Kidney Disease in Japan","status":"COMPLETED","sponsor":"Tanabe Pharma Corporation","startDate":"2018-02-14","conditions":"Anemia; Hemodialysis Dependent Chronic Kidney Disease","enrollment":323},{"nctId":"NCT05451940","phase":"PHASE1, PHASE2","title":"Hydroxyurea and EPO in Sickle Cell Disease","status":"COMPLETED","sponsor":"Julia Xu","startDate":"2023-05-25","conditions":"Anemia, Sickle Cell, Sickle Cell Disease","enrollment":17},{"nctId":"NCT07319468","phase":"NA","title":"Effect of Exercises on Hemodialysis","status":"NOT_YET_RECRUITING","sponsor":"Cairo University","startDate":"2026-01-01","conditions":"Hemodialytic Patients","enrollment":69},{"nctId":"NCT07300111","phase":"PHASE3","title":"A Study to Evaluate Efficacy and Safety of QLG1218(Daprodustat) in Chinese Hemodialysis (HD)-Dependent Subjects With Anemia Associated With Chronic Kidney Disease (CKD)","status":"NOT_YET_RECRUITING","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2025-12-31","conditions":"Anaemia","enrollment":100},{"nctId":"NCT07169643","phase":"PHASE3","title":"Darbepoetin in Patients Candidates for Liver Transplant. (EPO-LT Trial)","status":"RECRUITING","sponsor":"Fundacion Clinic per a la Recerca Biomédica","startDate":"2025-11-25","conditions":"Liver Transplant; Complications","enrollment":140},{"nctId":"NCT03810911","phase":"PHASE2","title":"Mechanisms of EPO-induced Hypertension","status":"TERMINATED","sponsor":"VA Office of Research and Development","startDate":"2021-01-04","conditions":"Chronic Kidney Disease, Blood Pressure, Anemia","enrollment":27},{"nctId":"NCT07130487","phase":"NA","title":"Project CARE: CAncer Risk Evaluation","status":"RECRUITING","sponsor":"Anita Y. Kinney, PhD, RN","startDate":"2025-11-19","conditions":"Primary Care","enrollment":210},{"nctId":"NCT03169881","phase":"PHASE3","title":"Darbepoetin Trial to Improve Red Cell Mass and Neuroprotection in Preterm Infants","status":"COMPLETED","sponsor":"NICHD Neonatal Research Network","startDate":"2017-09-20","conditions":"Neurocognitive, Neuroprotective, Neonatal","enrollment":650},{"nctId":"NCT04798339","phase":"PHASE1, PHASE2","title":"Canakinumab With Darbepoetin Alfa in PTs With Lower-Risk MDS Who Have Failed ESA","status":"ACTIVE_NOT_RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2021-03-30","conditions":"Myelodysplastic Syndromes","enrollment":13},{"nctId":"NCT07025460","phase":"PHASE4","title":"Darbepoetin Alfa Once Monthly Dosing Schedule Maintains Hemoglobin Concentration Comparable to Every 2 Weeks Dosing Schedule in Advanced Chronic Kidney Disease Patients Not on Dialysis: A Multicenter, Phase 4 Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gangnam Severance Hospital","startDate":"2019-12-19","conditions":"Chronic Kidney Disease","enrollment":40},{"nctId":"NCT00560404","phase":"PHASE3","title":"A Study of Subcutaneous Mircera for the Maintenance Treatment of Dialysis Patients With Chronic Renal Anemia.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2008-04","conditions":"Anemia","enrollment":233},{"nctId":"NCT07131280","phase":"NA","title":"National Collaborative Centre for Hepatic Regenerative Medicine (NC-CHRM): Single vs Repeated Cycle of Granulocyte Colony-Stimulating Factor (GCSF) & Darbepoetin in Early Decompensated Cirrhosis","status":"NOT_YET_RECRUITING","sponsor":"Institute of Liver and Biliary Sciences, India","startDate":"2025-09","conditions":"Decompensated Cirrhosis","enrollment":110},{"nctId":"NCT04588311","phase":"PHASE3","title":"ErythroPOietin Alfa to Prevent Mortality and Reduce Severe Disability in Critically Ill TRAUMA Patients","status":"RECRUITING","sponsor":"Australian and New Zealand Intensive Care Research Centre","startDate":"2020-11-09","conditions":"Trauma, Traumatic Injury, Traumatic Brain Injury","enrollment":2500},{"nctId":"NCT07025681","phase":"PHASE3","title":"PK, PD, Safety and Immunogenicity Study of Erythropoietin of Incepta Pharmaceuticals Ltd With Eprex (Janssen-Cilag).","status":"RECRUITING","sponsor":"Incepta Pharmaceuticals Ltd","startDate":"2025-04-24","conditions":"Healthy","enrollment":56},{"nctId":"NCT07002827","phase":"NA","title":"Effect of Single vs Repeated Cycles of a Combination of Granulocyte Colony Stimulating Factor and Darbepoetin vs Standard Medical Treatment on Immunometabolic Profile in Patient With Early Decompensated Cirrhosis.","status":"NOT_YET_RECRUITING","sponsor":"Institute of Liver and Biliary Sciences, India","startDate":"2025-05-30","conditions":"Decompensated Liver Cirrhosis","enrollment":60},{"nctId":"NCT06919861","phase":"PHASE1","title":"Pharmacokinetics, Pharmacodynamics, and Safety of Nanokine Produced by Nanogen Pharmaceutical Joint Stock Company","status":"NOT_YET_RECRUITING","sponsor":"Nanogen Pharmaceutical Biotechnology Joint Stock Company","startDate":"2025-06","conditions":"Natural Blood and Blood Product Toxicity","enrollment":44},{"nctId":"NCT04313153","phase":"PHASE3","title":"Trial Evaluating the Efficacy and Safety of Oral Vadadustat Once Daily (QD) and Three Times Weekly (TIW) for the Maintenance Treatment of Anemia in Hemodialysis Subjects Converting From Erythropoiesis-Stimulating Agents (ESAs)","status":"COMPLETED","sponsor":"Akebia Therapeutics","startDate":"2020-05-27","conditions":"Anemia","enrollment":319},{"nctId":"NCT05617833","phase":"PHASE1","title":"Safety of Erythropoietin and Melatonin for Very Preterm Infants With Intraventricular Hemorrhage","status":"RECRUITING","sponsor":"Johns Hopkins University","startDate":"2024-04-30","conditions":"Intraventricular Hemorrhage of Prematurity","enrollment":60},{"nctId":"NCT05078138","phase":"PHASE4","title":"Impact of Erythropoietin on Hematological Adaptations and Physical Performance","status":"COMPLETED","sponsor":"United States Army Research Institute of Environmental Medicine","startDate":"2021-09-01","conditions":"Exercise-Induced Anemia, Physical Performance","enrollment":8},{"nctId":"NCT05300477","phase":"PHASE4","title":"Pharmacological Countermeasures for High Altitude","status":"ACTIVE_NOT_RECRUITING","sponsor":"United States Army Research Institute of Environmental Medicine","startDate":"2022-05-27","conditions":"Hypobaric Hypoxia","enrollment":18},{"nctId":"NCT04036253","phase":"PHASE3","title":"Study of HEMAX PFS Versus EPREX/ ERYPO® in Predialysis Chronic Kidney Disease","status":"COMPLETED","sponsor":"Bio Sidus SA","startDate":"2018-02-28","conditions":"Anemia of Chronic Kidney Disease","enrollment":43},{"nctId":"NCT03223961","phase":"PHASE3","title":"A Trial Testing Early vs Late Onset of EPO Alfa Treatment in Lower Risk MDS","status":"ACTIVE_NOT_RECRUITING","sponsor":"Groupe Francophone des Myelodysplasies","startDate":"2018-03-26","conditions":"Myelodysplastic Syndromes","enrollment":124},{"nctId":"NCT01196715","phase":"PHASE3","title":"Comparison Study of Standard Care Against Combination of Growth Factors Agents for Low-risk Myelodysplastic Syndromes","status":"COMPLETED","sponsor":"Barts & The London NHS Trust","startDate":"2010-11-01","conditions":"Myelodysplastic Syndrome","enrollment":360},{"nctId":"NCT06764511","phase":"","title":"Evaluation of Response to Biosimilar Erythropoietin Alfa Therapy in Anemic Patients With Myelodysplastic Syndrome","status":"RECRUITING","sponsor":"IRCCS Azienda Ospedaliero-Universitaria di Bologna","startDate":"2024-08-30","conditions":"Myelodysplastic Syndromes (MDS)","enrollment":60},{"nctId":"NCT06670963","phase":"PHASE4","title":"Use of Epoetin Alfa and Iron Derisomaltose in Treatment of Anemia in Patients With Sepsis or Septic Shock: a Randomized Controlled Trial","status":"RECRUITING","sponsor":"Piotr Czempik","startDate":"2024-11-10","conditions":"Anemia, Sepsis, Septic Shock","enrollment":200},{"nctId":"NCT02278341","phase":"PHASE3","title":"Roxadustat in the Treatment of Anemia in End Stage Renal Disease (ESRD) Patients on Stable Dialysis","status":"COMPLETED","sponsor":"Astellas Pharma Europe B.V.","startDate":"2014-11-21","conditions":"Anemia, End Stage Renal Disease (ESRD)","enrollment":838},{"nctId":"NCT03682536","phase":"PHASE3","title":"A Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Participants Who Require Red Blood Cell Transfusions and Are ESA Naïve","status":"ACTIVE_NOT_RECRUITING","sponsor":"Celgene","startDate":"2019-01-02","conditions":"Myelodysplastic Syndromes","enrollment":363},{"nctId":"NCT05810311","phase":"PHASE2","title":"The Effect of Roxadustat on Renal Oxygenation in Diabetes Nephropathy","status":"NOT_YET_RECRUITING","sponsor":"Region Stockholm","startDate":"2025-06-01","conditions":"Diabetes Complications, Diabetes; Nephropathy (Manifestation)","enrollment":30},{"nctId":"NCT02021318","phase":"PHASE3","title":"Roxadustat in the Treatment of Anemia in Chronic Kidney Disease (CKD) Patients, Not on Dialysis, in Comparison to Darbepoetin Alfa","status":"COMPLETED","sponsor":"Astellas Pharma Europe B.V.","startDate":"2014-03-12","conditions":"Anemia in Chronic Kidney Disease in Non-dialysis Patients","enrollment":616},{"nctId":"NCT02988973","phase":"PHASE3","title":"A Study of Intermittent Oral Dosing of ASP1517 in Non-Dialysis Chronic Kidney Disease Patients With Anemia","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2017-01-12","conditions":"Chronic Kidney Disease","enrollment":334},{"nctId":"NCT02952092","phase":"PHASE3","title":"A Study of Intermittent Oral Dosing of ASP1517 in Hemodialysis Chronic Kidney Disease Patients With Anemia","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2016-11-30","conditions":"Hemodialysis Chronic Kidney Disease Patients With Anemia","enrollment":303},{"nctId":"NCT01888445","phase":"PHASE2","title":"A Study to Investigate the Effect of ASP1517 After Intermittent Oral Dosing in Dialysis Chronic Kidney Disease Patients With Anemia Compared With Darbepoetin as a Reference Drug","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2013-03-28","conditions":"Renal Anemia Associated With Chronic Renal Failure (CRF)","enrollment":130},{"nctId":"NCT06581055","phase":"","title":"A Retrospective Study to Describe Real-World Treatment Patterns and Clinical Outcomes Among Patients With Myelodysplastic Syndromes","status":"WITHDRAWN","sponsor":"Bristol-Myers Squibb","startDate":"2024-11-30","conditions":"Myelodysplastic Syndromes (MDS)","enrollment":""},{"nctId":"NCT02251041","phase":"PHASE2","title":"Combined Drug Approach to Prevent Ischemia-reperfusion Injury During Transplantation of Livers (CAPITL)","status":"COMPLETED","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2014-09","conditions":"Reperfusion Injury","enrollment":143},{"nctId":"NCT06352138","phase":"PHASE3","title":"Comparative Study of Two Recombinant Human Erythropoietin Products in Chronic Kidney Disease Patients","status":"NOT_YET_RECRUITING","sponsor":"Megalabs","startDate":"2025-07","conditions":"Anemia of Chronic Kidney Disease","enrollment":280},{"nctId":"NCT01471015","phase":"PHASE1, PHASE2","title":"Darbe Administration in Newborns Undergoing Cooling for Encephalopathy","status":"COMPLETED","sponsor":"University of Utah","startDate":"2012-09","conditions":"Hypoxic Ischemic Encephalopathy","enrollment":30},{"nctId":"NCT05265325","phase":"PHASE2","title":"A Study of AND017 to Treat Anemia in Chronic Kidney Disease Patients on Dialysis","status":"COMPLETED","sponsor":"Kind Pharmaceuticals LLC","startDate":"2023-05-03","conditions":"Renal Anemia","enrollment":175},{"nctId":"NCT06466785","phase":"PHASE3","title":"A Phase 3 Study of Efepoetin Alfa for Treatment of Anemia in Patients With Chronic Kidney Disease on Dialysis","status":"RECRUITING","sponsor":"Genexine, Inc.","startDate":"2024-01-25","conditions":"Anemia of Chronic Kidney Disease","enrollment":429},{"nctId":"NCT03079167","phase":"PHASE3","title":"PAEAN - Erythropoietin for Hypoxic Ischaemic Encephalopathy in Newborns","status":"COMPLETED","sponsor":"University of Sydney","startDate":"2016-05-14","conditions":"Hypoxic-Ischemic Encephalopathy","enrollment":313},{"nctId":"NCT00310232","phase":"PHASE3","title":"Epoetin Alfa in Advanced Non-Small Cell Lung Cancer (EPO-CAN-20)","status":"TERMINATED","sponsor":"Ontario Clinical Oncology Group (OCOG)","startDate":"2001-02","conditions":"Non-Small-Cell Lung Carcinoma, Lung Cancer, Anemia","enrollment":70},{"nctId":"NCT02876835","phase":"PHASE3","title":"Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Non-Dialysis (ASCEND-ND)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2016-09-27","conditions":"Anaemia","enrollment":3872},{"nctId":"NCT03446612","phase":"PHASE2","title":"Anemia Study in Chronic Kidney Disease (CKD) : Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat -Forearm Blood Flow (ASCEND-FBF)","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2019-01-10","conditions":"Anaemia","enrollment":6},{"nctId":"NCT03457701","phase":"PHASE2","title":"Anemia Studies in CKD: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat- Iron (ASCEND: Fe)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2019-07-30","conditions":"Anaemia","enrollment":15},{"nctId":"NCT04432662","phase":"PHASE2","title":"Darbepoetin in Neonatal Encephalopathy Trial","status":"RECRUITING","sponsor":"Imperial College London","startDate":"2021-05-28","conditions":"Neonatal Encephalopathy","enrollment":150},{"nctId":"NCT03308448","phase":"PHASE3","title":"Traumatic Optic Neuropathy Treatment Trial 2","status":"COMPLETED","sponsor":"Iran University of Medical Sciences","startDate":"2018-01-06","conditions":"Traumatic Optic Neuropathy","enrollment":93},{"nctId":"NCT02140736","phase":"","title":"Epoetin Alfa Biosimilar in the Management of Chemotherapy-Induced Symptomatic Anemia in Haematology and Oncology","status":"COMPLETED","sponsor":"Hospira, now a wholly owned subsidiary of Pfizer","startDate":"2009-09","conditions":"Chemotherapy-induced Symptomatic Anemia, Solid Tumors, Malignant Hemopathies","enrollment":2333},{"nctId":"NCT02987465","phase":"","title":"Evaluating the Effect of Standard-of-care Erythropoiesis-stimulating Agents on Forearm Blood Flow in Nondialysis-dependent Subjects With Anaemia Associated With Chronic Kidney Disease.","status":"COMPLETED","sponsor":"Cambridge University Hospitals NHS Foundation Trust","startDate":"2017-02-20","conditions":"Cardiovascular Diseases, Chronic Kidney Disease","enrollment":29},{"nctId":"NCT04330729","phase":"NA","title":"The Effect of Salicylate on Platelet Function in CKD (Chronic Kidney Disease) Patients Treated With Aranesp","status":"RECRUITING","sponsor":"Zealand University Hospital","startDate":"2020-04-15","conditions":"Erythropoietin Adverse Reaction","enrollment":60},{"nctId":"NCT04155125","phase":"PHASE3","title":"A Study of Efepoetin Alfa in Treating Anaemia Associated With Chronic Kidney Diseases Patient","status":"COMPLETED","sponsor":"PT Kalbe Genexine Biologics","startDate":"2020-07-02","conditions":"Anaemia Associated With Chronic Kidney Disease","enrollment":391},{"nctId":"NCT03071861","phase":"PHASE2","title":"Mild Encephalopathy in the Newborn Treated With Darbepoetin","status":"COMPLETED","sponsor":"University of New Mexico","startDate":"2017-12-01","conditions":"Neonatal Encephalopathy, Hypoxic-Ischemic Encephalopathy Mild","enrollment":28},{"nctId":"NCT03171818","phase":"PHASE2","title":"Darbepoetin for Ischemic Neonatal Stroke to Augment Regeneration","status":"UNKNOWN","sponsor":"UMC Utrecht","startDate":"2017-07-01","conditions":"PAIS, Neonatal Stroke, Perinatal Stroke","enrollment":80},{"nctId":"NCT02708914","phase":"PHASE3","title":"Study to Compare the Safety and Efficacy of UB-851 and Eprex®","status":"COMPLETED","sponsor":"UBI Pharma Inc.","startDate":"2016-03","conditions":"Renal Anemia","enrollment":269},{"nctId":"NCT05864261","phase":"PHASE4","title":"Pharmacokinetics Comparison Study of JT1801 and NESP® After Single Dose Administration in Chinese Health Male Volunteers","status":"COMPLETED","sponsor":"Yi Fang","startDate":"2023-05-15","conditions":"Renal Anemia","enrollment":74},{"nctId":"NCT03061565","phase":"","title":"Long Term Effects of Erythropoietin in Patients With Moderate to Severe Traumatic Brain Injury","status":"COMPLETED","sponsor":"Australian and New Zealand Intensive Care Research Centre","startDate":"2017-08-01","conditions":"Traumatic Brain Injury","enrollment":356},{"nctId":"NCT03339596","phase":"PHASE2","title":"Effects of Erythropoietin for Cognitive Side-effects of ECT","status":"COMPLETED","sponsor":"Martin Balslev Jørgensen","startDate":"2017-06-26","conditions":"ECT, Cognitive Impairment, Unipolar Depression","enrollment":60},{"nctId":"NCT00146562","phase":"PHASE2","title":"Pegfilgrastim and Darbepoetin Alfa in Support of Adjuvant Chemotherapy for Breast Cancer","status":"COMPLETED","sponsor":"Harold J. Burstein, MD, PhD","startDate":"2003-07","conditions":"Breast Cancer, Stage I Breast Cancer, Stage II Breast Cancer","enrollment":135},{"nctId":"NCT00666835","phase":"PHASE3","title":"Study to Evaluate the Efficacy and Safety of HX575 Hexal AG vs ERYPO® for the Treatment of Anemia in Hemodialysis Patients","status":"COMPLETED","sponsor":"Sandoz","startDate":"2004-04","conditions":"Anemia","enrollment":478},{"nctId":"NCT00060398","phase":"PHASE3","title":"Epoetin Alfa With or Without Dexamethasone in Treating Fatigue and Anemia in Patients With Hormone-Refractory Prostate Cancer","status":"COMPLETED","sponsor":"Eastern Cooperative Oncology Group","startDate":"2004-09-29","conditions":"Anemia, Fatigue, Prostate Cancer","enrollment":282},{"nctId":"NCT00049348","phase":"PHASE2","title":"Chemotherapy and Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer","status":"COMPLETED","sponsor":"Eastern Cooperative Oncology Group","startDate":"2003-10-13","conditions":"Pancreatic Cancer","enrollment":""},{"nctId":"NCT03315897","phase":"PHASE2","title":"Effects of Erythropoietin on Cognition and Neural Activity in Mood Disorders","status":"COMPLETED","sponsor":"Lars Vedel Kessing","startDate":"2017-07-05","conditions":"Bipolar Disorder, Cognitive Impairment, Unipolar Depression","enrollment":103},{"nctId":"NCT05768997","phase":"PHASE3","title":"High Dose IV Iron Plus ESA in Chemotherapy-induced Anemia","status":"UNKNOWN","sponsor":"Hallym University Medical Center","startDate":"2023-03-01","conditions":"Anemia","enrollment":312},{"nctId":"NCT02811263","phase":"PHASE3","title":"High-dose Erythropoietin for Asphyxia and Encephalopathy","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2017-01","conditions":"Neonatal Encephalopathy, Birth Asphyxia","enrollment":500},{"nctId":"NCT00858364","phase":"PHASE3","title":"Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy","status":"TERMINATED","sponsor":"Amgen","startDate":"2009-07-17","conditions":"Non-Small Cell Lung Cancer, Anemia, Cancer","enrollment":2549},{"nctId":"NCT00436748","phase":"PHASE3","title":"Study to Assess Darbepoetin Alfa Dosing for the Correction of Anemia in Pediatric Patients With Chronic Kidney Disease","status":"TERMINATED","sponsor":"Amgen","startDate":"2008-09-16","conditions":"Anemia, Chronic Kidney Disease, Kidney Disease","enrollment":116},{"nctId":"NCT02947438","phase":"PHASE3","title":"Biosimilar Erythropoietin in Anaemia Treatment (Maintenance Phase Study)","status":"COMPLETED","sponsor":"Shenyang Sunshine Pharmaceutical Co., LTD.","startDate":"2015-12","conditions":"Renal Anemia","enrollment":207},{"nctId":"NCT00093015","phase":"PHASE3","title":"Trial to Reduce Cardiovascular Events With Aranesp® Therapy (TREAT)","status":"COMPLETED","sponsor":"Amgen","startDate":"2004-08-01","conditions":"Kidney Disease, Diabetes Mellitus, Anemia","enrollment":4038},{"nctId":"NCT00358215","phase":"PHASE3","title":"RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial","status":"COMPLETED","sponsor":"Amgen","startDate":"2006-06-01","conditions":"Heart Failure, Anemia, Cardiovascular Disease","enrollment":2278},{"nctId":"NCT03572647","phase":"PHASE1","title":"Pharmacokinetics and Pharmacodynamics Assessment of Drug Eritromax Compared to Eprex in Healthy Subjects.","status":"COMPLETED","sponsor":"Azidus Brasil","startDate":"2012-11","conditions":"Renal Insufficiency, Chronic","enrollment":40},{"nctId":"NCT01685333","phase":"PHASE1","title":"PK and PD Crossover Study After Single Dose, Intravenous Administration of Two Epoetin Alfa, Human Recombinant Epoetin and Eprex, in Healthy Subjects.","status":"COMPLETED","sponsor":"Azidus Brasil","startDate":"2013-02-28","conditions":"Healthy","enrollment":28},{"nctId":"NCT01685359","phase":"PHASE1","title":"PK and PD Parallel Study After Multiple Dose, Intravenous Administration of Two Epoetin Alfa, Human Recombinant","status":"COMPLETED","sponsor":"Azidus Brasil","startDate":"2013-02-28","conditions":"Healthy","enrollment":80},{"nctId":"NCT05585658","phase":"PHASE1, PHASE2","title":"A Randomized, Double-blinded, Active Controlled Crossover Clinical Trial to Investigate PK, PD and Safety of GBPD002","status":"COMPLETED","sponsor":"Globe Biotech Limited","startDate":"2021-10-16","conditions":"Natural Blood and Blood Product Toxicity","enrollment":42},{"nctId":"NCT05080049","phase":"PHASE3","title":"Erythropoietin to Improve Critical Care Patient Outcomes","status":"UNKNOWN","sponsor":"University Hospital, Angers","startDate":"2022-01-28","conditions":"Anemia, Intensive Care","enrollment":42},{"nctId":"NCT03799627","phase":"PHASE2","title":"Study of Vadadustat in Hemodialysis Participants With Anemia Switching From Epoetin Alfa","status":"COMPLETED","sponsor":"Akebia Therapeutics","startDate":"2019-01-31","conditions":"Anemia, Dialysis-dependent Chronic Kidney Disease","enrollment":175},{"nctId":"NCT01652872","phase":"PHASE3","title":"Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease","status":"COMPLETED","sponsor":"Amgen","startDate":"2012-07-30","conditions":"Anemia in Chronic Kidney Disease Patients Not on Dialysis","enrollment":756},{"nctId":"NCT03683810","phase":"PHASE1","title":"The Effectiveness of Lactoferrin in the Management of Treatment-induced Anemia","status":"UNKNOWN","sponsor":"Cyprus University of Technology","startDate":"2019-01-14","conditions":"Anemia","enrollment":50},{"nctId":"NCT04484857","phase":"PHASE3","title":"Study of Roxadustat Conversion in Participants Receiving Stable ESA or as Initial Anemia Treatment in Hemodialysis Participants","status":"COMPLETED","sponsor":"Kyntra Bio","startDate":"2020-07-22","conditions":"Anemia Associated With End Stage Renal Disease","enrollment":283},{"nctId":"NCT05422755","phase":"","title":"The Clinical Study to Evaluate Immunogenicity of Epodion® in Anemia Associated With CKD Patients","status":"COMPLETED","sponsor":"PT. Daewoong Infion","startDate":"2019-09-30","conditions":"Chronic Kidney Disease (CKD)","enrollment":200},{"nctId":"NCT02865850","phase":"PHASE3","title":"Efficacy and Safety Study to Evaluate Vadadustat for the Correction or Maintenance Treatment of Anemia in Participants With Incident Dialysis-dependent Chronic Kidney Disease (DD-CKD)","status":"COMPLETED","sponsor":"Akebia Therapeutics","startDate":"2016-07","conditions":"Anemia, Dialysis-Dependent Chronic Kidney Disease","enrollment":369},{"nctId":"NCT05373303","phase":"NA","title":"The Clinical Study for Evaluating The Safety And Efficacy Of Epodion®","status":"COMPLETED","sponsor":"PT. Daewoong Infion","startDate":"2019-11-07","conditions":"Chronic Kidney Disease (CKD)","enrollment":82},{"nctId":"NCT02892149","phase":"PHASE3","title":"Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Participants With Dialysis-dependent Chronic Kidney Disease (DD-CKD)","status":"COMPLETED","sponsor":"Akebia Therapeutics","startDate":"2016-08","conditions":"Anemia, Dialysis-Dependent Chronic Kidney Disease","enrollment":3554},{"nctId":"NCT02680574","phase":"PHASE3","title":"Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Participants With Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD)","status":"COMPLETED","sponsor":"Akebia Therapeutics","startDate":"2016-02","conditions":"Anemia, Non-Dialysis-Dependent Chronic Kidney Disease","enrollment":1725},{"nctId":"NCT02648347","phase":"PHASE3","title":"Study to Evaluate Vadadustat for the Correction of Anemia in Participants With Non-dialysis-dependent Chronic Kidney Disease","status":"COMPLETED","sponsor":"Akebia Therapeutics","startDate":"2015-12","conditions":"Anemia, Non-Dialysis-Dependent Chronic Kidney Disease","enrollment":1751},{"nctId":"NCT01235923","phase":"PHASE2","title":"Randomized Study of Weekly Erythropoietin Dosing in Preterm Infants","status":"COMPLETED","sponsor":"University of New Mexico","startDate":"2006-04","conditions":"Preterm Infants","enrollment":20},{"nctId":"NCT01147666","phase":"PHASE2","title":"Study of Roxadustat (FG-4592) in Participants With End-Stage Renal Disease Receiving Maintenance Hemodialysis","status":"COMPLETED","sponsor":"Kyntra Bio","startDate":"2010-05-17","conditions":"End Stage Renal Disease, Anemia","enrollment":161},{"nctId":"NCT02879305","phase":"PHASE3","title":"Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Dialysis (ASCEND-D)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2016-09-28","conditions":"Anaemia, Aspergillosis, Allergic Bronchopulmonary","enrollment":2964},{"nctId":"NCT02564796","phase":"PHASE2","title":"Erythropoietin to Prevent Unnecessary Transfusions In Patients With Cyanotic CHD - A Prospective Control Trial","status":"TERMINATED","sponsor":"University of California, San Diego","startDate":"2016-11","conditions":"Cyanotic Congenital Heart Disease, Anemia, Cyanosis","enrollment":4},{"nctId":"NCT04215120","phase":"PHASE3","title":"Desidustat in the Treatment of Anemia in CKD on Dialysis Patients","status":"COMPLETED","sponsor":"Zydus Lifesciences Limited","startDate":"2020-01-04","conditions":"Chronic Kidney Disease Stage 5 on Dialysis","enrollment":392},{"nctId":"NCT04012957","phase":"PHASE3","title":"Desidustat in the Treatment of Anemia in CKD","status":"COMPLETED","sponsor":"Zydus Lifesciences Limited","startDate":"2019-07-20","conditions":"Chronic Kidney Disease Stage 3, Anemia, Chronic Kidney Disease Stage 4","enrollment":588},{"nctId":"NCT02273726","phase":"PHASE3","title":"Study to Evaluate the Efficacy and Safety of Roxadustat in the Treatment of Anemia in Participants With ESRD on Stable Dialysis","status":"COMPLETED","sponsor":"Kyntra Bio","startDate":"2015-01-15","conditions":"CKD Anemia in Stable Dialysis Patients","enrollment":741}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":41,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["procrit, epoetin alfa","Nanokine","Eprex","Espogen (LG Life Science Ltd.)"],"phase":"phase_3","status":"active","brandName":"Erythropoietin alfa","genericName":"Erythropoietin alfa","companyName":"Bio Sidus SA","companyId":"bio-sidus-sa","modality":"Biologic","firstApprovalDate":"","aiSummary":"Erythropoietin alfa is a recombinant human erythropoietin that stimulates red blood cell production by binding to erythropoietin receptors on bone marrow progenitor cells. Used for Anemia associated with chronic kidney disease, Anemia in patients with cancer receiving chemotherapy, Anemia in patients with HIV infection.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":3,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}